ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 998

β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10

Georg Pongratz1, Clemens Wiest2, Madlen Melzer2 and Rainer Straub3, 1Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, 2University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine, University Hospital Regensburg, Regensburg, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, B cells, interleukins (IL), Neuroendocrine Immune (NEI), regulatory cells and rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells decreases disease activity. However, B cells from unimmunized mice do not adequately increase IL-10. Therefore, we test the hypothesis that sensitivity to catecholamines changes during CIA. Furthermore, we wanted to test if human peripheral blood B cells from osteoarthritis (OA) and rheumatoid arthritis (RA) patients also increase IL-10 following a β2-adrenergic stimulus.

Methods

FACS to determine AR pathway related proteins (β2-adrenoceptor, G-protein coupled receptor kinase (GRK) 2, phophorylated and unphosphorylated mitogen activated protein kinase p38, and cAMP responsive element binding protein (CREB)) in B cells at different timepoints during CIA. Unstimulated splenic B cells and B cells stimulated with terbutalin, a β2-AR agonist, were used. Human B cells were isolated from peripheral blood of patients with OA or RA and stimulated under different conditions with and without terbutalin. IL-10 protein level was determined by ELISA after 5 days of culture.

Results

In the course of CIA the percentage of β2-AR+ B cells increased and stayed above baseline (ANOVA p<0.05). In contrast, the mean fluorescence intensity (MFI) as measure for the number of receptors per cell remained unchanged. MFI for GRK2 decreased and stayed low from day 6 p.i. (ANOVA p<0.0001). The relative increase in phosphorylation of p38 (ANOVA p<0.001) and CREB (ANOVA p<0.001) following a β2-AR stimulus was augmented starting at day 18 p.i. with a maximum response at day 55 p.i. in the late phase of CIA. In human B cells, similar mechanisms are in place, because β2-AR stimulation of RA, but not OA B cells increased IL-10. 

Conclusion

The current data show, that B cells become more sensitive to β2-AR stimuli in the course of CIA, possibly due to a decrease in GRK2 and increase in the percentage of β2-AR expressing splenic B cells. Increased catecholamine sensitivity might support B cell and IL-10 mediated anti-inflammatory mechanisms primarily in the late phase of CIA. A similar mechanism is observed in human peripheral B cells and might be used to improve treatment of autoimmune arthritis.


Disclosure:

G. Pongratz,
None;

C. Wiest,
None;

M. Melzer,
None;

R. Straub,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/%ce%b22-adrenoceptor-signal-is-augmented-in-b-cells-in-the-course-of-arthritis-to-increase-il-10/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology